3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
4
NIH
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Conditions
Neoplasms
3
Skin Diseases
2
Neoplasms by Site
2
Carcinoma, Renal Cell
2
Uveal Melanoma
1
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Uterine Cervical Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Prostatic Neoplasms
1
Precancerous Conditions
1
Neoplasm Metastasis
1
Kidney Neoplasms
1
Hematologic Diseases
1
Genital Neoplasms, Female
1
Genital Diseases, Female
1
Genital Diseases
1
Female Urogenital Diseases and Pregnancy Complications
1
Communicable Diseases
1
Breast Neoplasms
1
Breast Diseases
1
Autoimmune Diseases
1
Interventions
pembrolizumab
44
Carboplatin
28
Cisplatin
26
Paclitaxel
24
Bevacizumab
21
human papillomavirus vaccine, L1 type 16, 18
16
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
14
atezolizumab
11
Papillomavirus Vaccines
11
Nivolumab
10
tisotumab vedotin
8
Vaccines, Synthetic
8
Gemcitabine
8
Colposcopy
8
Topotecan
7
fludarabine
6
Vaccines
6
Injections
6
Cyclophosphamide
6
spartalizumab
5
balstilimab
5
Pemetrexed
5
Irinotecan
5
Fulvestrant
5
Docetaxel
5
zimberelimab
4
durvalumab
4
Vinorelbine
4
Ipilimumab
4
Interleukin-2
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Uterine Cervical Neoplasms
×
Watchful Waiting
×
Clear all
NCT06815939
2026-01-29
OPTICS
DL Analytics
Phase NA
Recruiting
10,000 enrolled